Previous 10 | Next 10 |
2023-12-27 13:00:46 ET Summary CareDx, Inc is a small diagnostic firm that develops and commercializes diagnostic solutions for transplant patients and caregivers. The stock has soared over the past two months thanks to better than expected Q3 results, the overall rally in the mar...
CareDx Expands Reach of its Transplant Pharmacy Services by Offering NFT Patients Help in Navigating the Complexity of Immunosuppression Medications and Adherence CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercializa...
2023-11-28 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-09 12:31:36 ET CareDx ( NASDAQ: CDNA ) shares jumped as much as 26% on Thursday after the medical equipment firm reported better-than-expected third quarter results and raised revenue outlook for 2023. Q3 revenue of $67.2M was well ahead of consensus, but fell 15...
2023-11-09 10:00:37 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
2023-11-08 20:13:08 ET CareDx, Inc (CDNA) Q3 2023 Results Conference Call November 08, 2023 04:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, Managing Director Alex Johnson - President of Patient and Testing Services Abhishek Jain - Chief Financi...
2023-11-08 16:15:02 ET More on CareDx CareDx: Diversification Strategies Vs. Core Weaknesses CareDx Q3 2023 Earnings Preview CareDx says Reginald Seeto to step down, board to initiate CEO search Seeking Alpha’s Quant Rating on CareDx Historical...
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the third quarter end...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
2023-11-05 23:46:57 ET In the upcoming week of November, investors can anticipate a flurry of quarterly reports from major companies, promising significant market activity. Notable among them is Disney ( NYSE: DIS ), a household name set to disclose its financial performance. ...
News, Short Squeeze, Breakout and More Instantly...
CareDx Inc. Company Name:
CDNA Stock Symbol:
NASDAQ Market:
2024-06-20 11:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in Clinically Stable Patients and AlloSure Kidney dd-cfDNA Levels were Elevated Pri...
AI-Derived AlloView Results Correlate with Presence and Type of Biopsy Proven Kidney Rejection Longitudinal Monitoring with AlloSure Kidney Enables Earlier Identification of Graft Injury and Assessment of Rejection Treatment KOAR Data Show Kidney Biopsies Informed by AlloSure Dete...